Search This Blog

Thursday, January 2, 2020

Arena Pharma teams up with Beacon Discovery in immune/inflammatory space

Arena Pharmaceuticals (NASDAQ:ARNA) inks a multi-year collaboration agreement with Beacon Discovery aimed at developing novel drugs across a range of G protein-coupled receptor (GPCR) targets for the potential treatment of immune and inflammatory disorders.
Beacon will be responsible for drug discovery while Arena will be responsible for development and commercialization. Financial terms are not disclosed.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.